DOAC Formulary Review Service

Scope of Service

The MMS service is a clinical therapy review service aligned to support local and national guidance in relation to the prescribing of best value DOAC therapy.

The review of high cost DOAC prescribing will be delivered in line with a focus as detailed below:

• Screen to highlight patients prescribed high cost DOAC for stroke prevention in AF

• Screen CrCl and weights to establish if current DOAC dosing is appropriate

• Cohort reviewed to optimise and potentially change DOAC to a low-cost generic option eg. rivaroxaban or apixaban

In order to streamline the process and save valuable admin & GP time, we request you to provide practice details and consider GP approval to pre-authorise pharmacist led changes to DOAC therapy in accordance with the service protocol.